A month after a manufacturing hiccup led to a CRL, CorMedix CEO will retire
After more than 5 years at the helm of New Jersey-based biopharma CorMedix, Khoso Baluch is retiring, and the move has triggered a ripple of change within its executive leadership team, leading CFO Matt David to take over as interim CEO, while maintaining his current role.
The departure comes about a month after delays at a contract manufacturer led to the resubmission of a new drug application for DefenCath, an antibacterial and antifungal treatment to prevent bloodstream infections in patients undergoing chronic hemodialysis. The drug was granted fast-track designation by the FDA, but delays at the CMO’s site led to a complete response letter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.